Cat. #154616
ZR-75-1 [XIV-55] cell line
Cat. #: 154616
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lambert Dorssers
Institute: Erasmus University Medical Center (Erasmus MC)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: ZR-75-1 [XIV-55] cell line
- Cancer: Gynaecologic cancer
- Cancers detailed: Mammary ductal carcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: ZR-75-1
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype. Retroviral insertion mutagenesis was used to generate this cell line in order to elucidate the molecular mechanisms underlaying endocrine therapy failure. Using this method the main genes conferring estrogen independence in human breast cancer cells where identified. Genes located in the immediate proximity of the retroviral integration site were characterised. Out of 15 candidate breast cancer antigen resistance (BCAR) genes, seven (AKT1, AKT2, BCAR1, BCAR3, EGFR2, GRB7 and TRERF1/BCAR2) were shown to directly underline estrogen independence. This cell line is part of a panel of 71 cell lines (Cat No 154549-154619) plus the parental (Cat No 154547).These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity.
- Production details: ZR-75-1 cells were infected with amphotropic, defective murine retrovirus and plated in medium containing 1uM of 4-hydroxy-tamoxifen. Within 5 weeks after the start of selection proliferating colonies were individually picked and expanded to stable cell lines
- Biosafety level: 1
Target Details
- Target: Breast cancer anti-estrogen resistance genes; BCAR3
Applications
- Application notes: Cell line with established retrovirus target responsible for estrogen independence: BCAR3
Handling
- Format: Frozen
- Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine calf serum (RBCS)
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.
